Table 2.
Clinical outcomes within 3 months after MVr
| Bleeding events | Group A: VKA (N = 325) | Group B: aspirin (N = 144) |
|---|---|---|
| Major bleeding | 21 (6.8)a | 14 (9.1) |
| Site | ||
| Chest | 20 | 12 |
| GI tract | 0 | 1 |
| Unknown | 1 | 1 |
| Fatal bleeding | 1 | 1 |
| Thromboembolic events | 8 (2.6) | 2 (1.6) |
| Type | ||
| Ischemic stroke | 4 | 1 |
| TIA | 4 | 0 |
| Left atrial thrombus | 0 | 1 |
| Fatal ischemic stroke | 0 | 1 |
GI gastrointestinal, TIA transient ischemic attack, MI myocardial infarction, DVT deep venous thrombosis
aNumbers in parenthesis are cumulative incidence